CHATSWORTH, Calif. Natrol on Friday announced that Nutra Acquisition Company, an indirect subsidiary of Plethico Pharmaceuticals, successfully completed its cash tender offer for outstanding shares of Natrol’s common stock at $4.40 net per share in cash.
The deal was valued at $80.8 million.
Natrol entered into a merger agreement with Plethico and Nutra Acquisition Nov. 18.
As a further result of the merger, Natrol has become an indirect subsidiary of Plethico, Natrol’s common stock will no longer be listed and traded on the Nasdaq Global Market.
Morgan Joseph & Co. served as financial advisor to Natrol and international law firm, Greenberg Traurig, acted as Natrol’s public merger and acquisition counsel.